The study of stereotactic body radiation therapy in people with breast cancer

Memorial Sloan Kettering Cancer Center is commencing recruitment for the clinical trial of the A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer.

The conditions are Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer.

The trial officially began on the September 6, 2022 and is planned to complete on September 6, 2025.

The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. This combination of SBRT to a single metastatic site and usual drug therapy may prevent participants' cancer from worsening in other metastatic sites or spreading.

The population that can be enrolled into this study includes:

• Age 18 or older and willing and able to provide informed consent;
• Metastatic breast cancer, biopsy proven;
• ER+/HER2-;
• History of at least 6 months, sustained response to systemic therapy;
• Isolated site of disease progression on FDG PET scan;
• Consented to 12-245;
• ECOG performance status 0-1.

The link to the complete study profile and inclusion/exclusion criteria: https://ichgcp.net/clinical-trials-registry/NCT05534438.